Geoffrey Krampitz, MD, Department of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, identifies tumorigenic cells and therapeutic targets in patients with pancreatic neuroendocrine tumors (pNETs).

Anti-CD47 agents and their safety profiles are currently being investigated in a phase I clinical trial, Krampitz explains. Community oncologists, he adds, should be aware of this class of drugs eventually coming down the pipeline.

Regarding safety, preclinical models reported low-grade anemia associated with anti-CD47 agents. However, this has not yet been observed in the phase I data, Krampitz adds.

Videos

Geoffrey Krampitz, MD, Department of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, identifies tumorigenic cells and therapeutic targets in patients with pancreatic neuroendocrine tumors. 


Geoffrey Krampitz, MD

Articles

Dr. Krampitz on Therapeutic Targets in pNETs